Post-Market Intelligence Retainer & Ongoing PMS Governance

In medical device and life sciences contexts, PMS usually means post-market surveillance, the structured process of collecting and analyzing data after a product is on the market. PMC can refer to post-market clinical follow-up or broader post-market commitments, depending on the framework. Together, they help manufacturers monitor safety, performance, complaints, reportability, and emerging risks throughout the product lifecycle.

Postmarketing monitoring helps identify safety issues, rare adverse events, long-term performance concerns, and real-world use patterns that may not appear during premarket studies. While this page focuses on medical devices, the principle is similar: regulators expect manufacturers to actively monitor products after launch, assess benefit-risk continuously, and take timely action when new signals or compliance obligations emerge.

A post-market intelligence retainer typically includes ongoing monitoring of regulatory updates, standards revisions, enforcement trends, public adverse event databases, and market-specific guidance relevant to your device portfolio. It may also include periodic briefings, actionable summaries, signal reviews, and recommendations that help your team update PMS activities, complaint processes, risk files, and reporting decisions before issues escalate.

Ongoing PMS governance creates structure around complaint review, trend analysis, reportability assessment, PMS reporting, and cross-functional escalation. Instead of treating post-market work as isolated tasks, it connects complaints, vigilance, CAPA, risk management, and clinical evaluation into one governed system. That improves consistency, supports audit readiness, and helps manufacturers respond faster to emerging safety or compliance concerns.

Yes. Elexes supports reportability assessments and post-market governance activities aligned with FDA Medical Device Reporting requirements, EU MDR vigilance obligations, and related global frameworks. Support can include reviewing complaint events, documenting decision rationale, preparing required reports, and helping ensure submissions are accurate, complete, and made within applicable regulatory timelines.

Signal review frequency should be defined within your PMS procedures and aligned to device risk, complaint volume, market footprint, and regulatory commitments. Many manufacturers benefit from monthly or quarterly reviews, with immediate escalation for serious events. Regular analysis helps detect trends across lots, geographies, or product families early enough to support CAPA, risk updates, and timely regulatory action.

It should, and strong PMS governance is designed to do exactly that. Complaint trends, literature findings, field feedback, and reportable events should feed into risk management updates, CAPA initiation, clinical evaluation refreshes, and change assessments where appropriate. This integration is essential because regulators expect post-market data to drive real quality and safety decisions, not just periodic documentation.

Yes. This service is especially valuable for startups, scaling manufacturers, and lean teams that need ongoing post-market oversight without building a full internal RAQA department. Elexes can act as an embedded support function, providing continuity in complaint governance, PMS reporting, intelligence monitoring, and regulatory decision-making while reducing the burden on internal headcount.